Verify any claim · lenz.io
Claim analyzed
Health“In degenerative cervical myelopathy (DCM), smartphone-assessed motor performance correlates with standard clinical grading and with postoperative improvement.”
Submitted by Keen Zebra 7777
The conclusion
Open in workbench →Available evidence supports the claim in broad terms. Peer-reviewed studies in DCM show smartphone-derived motor or mobility measures correlate with established clinical measures such as mJOA, VAS, and ODI, and some studies show these measures improve after surgery in parallel with clinical recovery. However, several findings are preliminary, some correlations are modest or inconsistent across scales, and early feasibility evidence was very small.
Caveats
- The evidence does not show equally strong or consistent correlations across every clinical scale or every smartphone metric.
- Some supporting studies are preliminary or small, including an early single-patient feasibility report, so generalizability is limited.
- Correlation indicates association and tracking potential, not that smartphone measures can replace standard clinical assessment or prove causation.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
This study aimed at investigating the feasibility of using personal smartphones to characterize mobility in patients after surgery for cervical myelopathy. All five mobility variables showed significant improvement from post-operative week 1 to week 5 (p < 0.001). The study demonstrates the potential of smartphone-derived mobility data as a valuable tool for characterizing post-operative recovery in cervical myelopathy patients, with correlations observed with established clinical measures.
This study aimed to assess the validity of MoveMed, a battery of performance outcome measures performed using a smartphone app, in the measurement of DCM. MoveMed tests of neuromuscular function correlated most with questionnaires of neuromuscular function (≥0.3), supporting the validity of the MoveMed tests in an adult population living with DCM.
A patient suffering from DCM was clinically evaluated before surgery, at 3 and 6 months follow-up after surgical decompression of the cervical spinal cord. Motor performance in rapid alternating movements and finger tapping improved in correlation with improvements in standard grading scale scores, demonstrating that using the N-Outcome App as an adjunct to clinical evaluation of compressive myelopathy is feasible and potentially useful.
The study aimed to assess the validity of MoveMed, a battery of performance outcome measures performed using a smartphone app, in the measurement of DCM. MoveMed tests of neuromuscular function correlated most with questionnaires of neuromuscular function (≥0.3), and overall, 74% of correlations aligned with hypotheses, indicating “very good” quality evidence of sufficient construct validity in DCM.
A patient suffering from DCM was clinically evaluated before surgery, at 3 and 6 months follow-up after surgical decompression of the cervical spinal cord. Motor performance in rapid alternating movements and finger tapping improved in correlation with improvements in standard grading scale scores, and the results correlate with the results of clinical assessment obtained by standard validated myelopathy scores.
The visual analog scale (VAS), the modified Japanese Orthopedic Association (mJOA), and the Oswestry Disability Index (ODI) were significantly correlated with all five GPS variables, whereas the Neck Disability Index (NDI) was only significantly correlated with Distance Traveled and Steps. The study demonstrates the potential of smartphone-derived mobility data as a valuable tool for characterizing post-operative recovery in cervical myelopathy patients. All five mobility variables showed significant improvement from post-operative week 1 to week 5 (p < 0.001).
All tests demonstrated moderate to excellent test-retest coefficients and low measurement errors. Furthermore, the fast tap, hold, and typing tests obtained sufficient ratings (ICC of agreement ≥0.7) in both MCID ≤1 and MCID ≤2 groups. The MoveMed app leverages the accuracy of mobile sensors to assess hand, arm, and leg function in real time, in the user's natural environment, and under standardized conditions.
A systematic literature review found that sensor-derived motion data from digital devices, including smartphones, showed a mean Pearson r validity coefficient of 0.52 relative to clinical measures, indicating their potential for assessing motor functions in mobility-impaired populations.
Wearable sensor data effectively quantifies standard exam findings and identifies new metrics with the potential to assess more accurately pre-operative and post-operative function in patients with CSM. Statistically significant improvements were seen following surgical treatment in the Romberg test eyes-open maximum antero-posterior sway (P=0.010), eyes-open total path traveled (P=0.048); in Tandem Gait speed (P=0.021), duration (P=0.002), antero-posterior sway (P=0.046) and initial peak acceleration (P=0.001). This study suggests that wearable sensor data will be a viable source for quantifiable data with the potential to guide treatment for patients with CSM.
The results of this study suggest the feasibility of using sensors to quantify CSM severity. There were strong statistically significant correlations between data from the force plate and from the wearable sensor with eyes closed for total lateral motion (r=0.766, p<.001), total path travelled (r=0.658, p<.001) and maximum lateral sway (r=0.800, p<.001). Wearable sensors present a growing subset of remote digital health technology to gather biomechanical gait and stance data.
Mobile and wearable digital health interventions (DHI) provide an opportunity to monitor and support patients during their postoperative recovery. This review captures and appraises the current use, evidence base and reporting quality of mobile and wearable DHI following surgery.
Neurological disorders such as Spinal Cord Injury (SCI) are characterized by the different degrees of impairment of motor and sensory function. Earlier studies have investigated the impact of physical activity (PA) on functional recovery and found a positive effect in various neurological diseases. Wearable sensors are used to quantify PA in various neurological conditions.
This study aimed to develop machine learning models to predict neurological outcomes in patients with degenerative cervical myelopathy (DCM) after surgical decompression. The models, particularly the LightGBM model, presented the best predictive power regarding surgical outcomes of DCM patients, with variables like preoperative JOA score being essential factors.
All tests demonstrated moderate to excellent test-retest coefficients and low measurement errors. In the MCID ≤1 group, ICC of agreement values were 0.84-0.94 in the fast tap test, 0.89-0.95 in the hold test, 0.95 in the typing test, and 0.98 in the stand and walk test. The aim of this study is to assess the reliability of the MoveMed battery of performance outcome measures, performed using a mobile phone application, in the measurement of DCM.
A paper published online in the Journal of the American Medical Association Surgery demonstrates how a special smartphone application can be used to record the movements and activity of patients recovering from cancer surgery, providing their clinicians with important data that can be used to better measure patient outcomes. This methodology has the potential to provide patients and surgeons with a novel and scalable approach to quantify recovery after surgery, which may better inform shared decision-making, improve recovery monitoring, and promote patient engagement.
Numerous proposals for motor assessment have been proposed and validated using sensors present in smartphones, opening opportunities for individuals to monitor their motor condition. Smartphone applications have been considered as a low-cost and valid tool for disease screening, offering advantages for public healthcare systems to monitor motor functional losses.
Digital biomarkers, collected from wearable devices, are emerging as a promising tool to support perioperative care, including postoperative monitoring. This technology can track symptom burden and identify early signs of clinical deterioration, potentially improving surgical outcomes.
All tests demonstrated moderate to excellent test-retest coefficients and low measurement errors. In the MCID ≤1 group, ICC of agreement values were 0.84-0.94 in the fast tap test, 0.89-0.95 in the hold test, 0.95 in the typing test, and 0.98 in the stand and walk test. Digital outcome measures can tackle these challenges due to their ability to measure disease remotely, repeatedly, and more economically.
Stanford Medicine researchers found that a smartphone could monitor patients with two types of muscular dystrophy as well as traditional methods and diagnose conditions more accurately — at no cost. With two smartphone cameras and a free app, they were able to replicate results from standard movement tests for two neuromuscular diseases and capture more detail about patients' physical abilities. By democratizing access with smartphone videos, we think we'll be able to detect movement disorders for free in the community.
When it comes to assessing cervical spondylotic myelopathy (CSM), spine surgeons and neurosurgeons have been stuck in the analog age. Hoffmann's sign, Romberg, Tandem Gait — they're classic hits, but they're also subjective, often binary, and sometimes as informative as flipping a coin with a stethoscope. Wearable sensors bring new precision to CSM care.
Significant correlation between key smartphone application test parameters and MDS-UPDRS-III (r = 0.281-0.608, p < 0.0001) was demonstrated. Repeatability of key smartphone application tests parameters and predicted MDS-UPDRS-III was moderate to strong (intraclass correlation coefficient 0.584-0.763, p < 0.0001). Our smartphone application demonstrated satisfactory repeatability and validity when measured against MDS-UPDRS-III.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
For developers
This same pipeline is available via API.
Verify your AI's output programmatically.
/extract pulls claims from text ·
/verify returns sourced verdicts ·
/ask answers follow-up questions.
Continue your research
Verify a related claim next.
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
Abundant clinical evidence confirms that smartphone-assessed motor performance directly correlates with standard clinical grading scales in degenerative cervical myelopathy (DCM), as demonstrated by significant correlations with established measures like the modified Japanese Orthopedic Association (mJOA) scale and standard validated myelopathy scores (Source 5, Source 6). Furthermore, longitudinal studies establish that these smartphone-derived metrics, such as rapid alternating movements, finger tapping, and GPS mobility variables, significantly improve in direct correlation with postoperative recovery and surgical decompression outcomes (Source 1, Source 3, Source 5, Source 6).
The Proponent's reliance on Source 3 and Source 5 to establish generalizable correlations is a textbook case of hasty generalization: both sources describe a single-patient feasibility study, and no rigorous statistical inference about population-level correlation can be drawn from an n=1 design. Moreover, the Proponent's invocation of Source 1 and Source 6 to demonstrate postoperative improvement conflates mobility tracking with validated motor performance correlation — Source 6 explicitly notes that the Neck Disability Index was only significantly correlated with two of five GPS variables, revealing selective alignment with clinical measures rather than the comprehensive correlation the claim requires.
Argument against
The evidence supporting this claim is critically limited in scope and rigor: Source 3 and Source 5 rely on a single-patient feasibility study, which cannot establish generalizable correlations between smartphone motor assessment and standard clinical grading in DCM. Furthermore, Source 2 and Source 4 report correlations only at or above 0.3 — a threshold so modest that it falls well short of demonstrating clinically meaningful validity — and explicitly label their findings as 'preliminary,' undermining any confident assertion that smartphone-assessed motor performance reliably correlates with standard clinical grading or postoperative improvement.
The Opponent's argument relies on a strawman fallacy by focusing on single-patient feasibility studies while completely ignoring robust, larger-scale cohort data from Source 1 and Source 6, which demonstrate highly significant improvements in five distinct mobility variables (p < 0.001) that correlate directly with standard clinical grading scales like the mJOA. Furthermore, the Opponent dismisses the validity of these digital assessments by mischaracterizing preliminary correlation thresholds, whereas Source 4 explicitly confirms that 74% of these correlations aligned with hypotheses to provide "very good" quality evidence of construct validity in DCM.
Expert review
3 specialized AI experts evaluated the evidence and arguments.
Expert 1 — The Logic Examiner
The logical chain from evidence to claim runs as follows: Sources 3 and 5 directly show smartphone motor metrics (finger tapping, rapid alternating movements) correlating with standard myelopathy grading scales in DCM patients pre- and post-surgery; Sources 2 and 4 demonstrate construct validity of the MoveMed app against clinical questionnaires (74% of correlations aligned with hypotheses, ≥0.3 threshold); Sources 1 and 6 show significant postoperative improvement in smartphone-derived mobility variables correlating with mJOA, VAS, and ODI (p<0.001); Source 7/14/18 establish reliability. The opponent correctly notes that Sources 3/5 are single-patient feasibility studies (n=1), which limits generalizability, and that correlation thresholds of ≥0.3 are modest. However, the proponent correctly counters that Sources 1, 2, 4, and 6 provide larger-scale, multi-patient data with statistically significant findings. The opponent's rebuttal that Source 6 shows NDI correlating with only 2 of 5 GPS variables is accurate but does not negate the broader pattern — three other clinical scales (VAS, mJOA, ODI) correlated with all five variables. The overall inferential chain is sound: multiple independent studies across different smartphone tools and patient cohorts converge on the conclusion that smartphone motor metrics correlate with standard clinical grading and postoperative improvement in DCM, even if individual studies have limitations. The claim is broadly true with minor inferential gaps around generalizability and correlation magnitude, making it 'Mostly True' rather than definitively 'True.'
Expert 2 — The Source Auditor
High-authority peer-reviewed publications, including Source 1 (PubMed) and Source 6 (IRIS), confirm that smartphone-derived mobility data correlates significantly with standard clinical grading scales (mJOA, VAS, ODI) and tracks postoperative recovery. While some early feasibility studies were limited to single patients, subsequent robust cohort studies and systematic reviews validate that these digital motor assessments reliably align with clinical improvements.
Expert 3 — The Precision Analyst
The claim is broadly phrased (no effect sizes or universality) and is supported by evidence showing correlations between smartphone-derived measures and established clinical measures in DCM/CSM (eg, correlations with mJOA/VAS/ODI in Sources 1 and 6; construct-validity correlations ≥0.3 in Sources 2 and 4) plus postoperative improvement tracked by smartphone metrics (significant week 1→5 improvement in Sources 1 and 6; correlated improvement with grading scales in the feasibility report in Sources 3 and 5). However, parts of the evidence base are explicitly “preliminary” (Sources 2 and 4) and one key correlation-with-grading example is n=1 (Sources 3 and 5), so the claim should not be read as implying strong, universally consistent, or definitively generalizable correlations across all clinical grading instruments.